Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05495204 · ClinicalTrials.gov registry record
External Comparison of Ibalizumab in Trials vs. Other Regimens in OPERA
A clinical trial, sponsored by Epividian.
- Completed
- Registry status
- 141
- Enrollment target
NCT05495204 is a clinical trial that has completed, run by Epividian. The registered enrollment target is 141 participants.
The verdict
NCT05495204 has completed, sponsored by Epividian.
- COMPLETED
- Registry status
- 141 participants
- Enrollment target
Study Summary
Among heavily treatment experienced people living with HIV, the virologic effectiveness of ibalizumab + optimized background regimen from two clinical trials will be compared to non-ibalizumab-containing regimens in routine clinical care in the OPERA cohort.
Interventions
- DRUG Ibalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 141 participants |
| Start Date | 2022-08-05 |
| Est. Completion | 2023-02-20 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05495204
The ClinicalTrials.gov registry entry for NCT05495204 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 141 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Epividian, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ibalizumab is the first listed.
NCT05495204 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05495204 about?
NCT05495204 is a clinical study titled "External Comparison of Ibalizumab in Trials vs. Other Regimens in OPERA". Among heavily treatment experienced people living with HIV, the virologic effectiveness of ibalizumab + optimized background regimen from two clinical trials will be compared to non-ibalizumab-containing regimens in routine clinical care in the OPERA cohort.
What is the current status of trial NCT05495204?
This trial is currently completed. The enrollment target is 141 participants. The study started on 2022-08-05. Estimated completion is 2023-02-20.
What interventions are being tested in trial NCT05495204?
The interventions under investigation include: Ibalizumab (DRUG).
Who is sponsoring clinical trial NCT05495204?
This trial is sponsored by Epividian, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.